11th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV (IWADR) 26-28 October 2009, Philadelphia
20 February 2010. Related: Conference reports, Side effects.
Side effects
GSK issues Dear Doctor letter in the US: fosamprenavir and cardiovascular risk
16 February 2010. Related: Antiretrovirals, Side effects.
HIV disease and renal function
15 February 2010. Related: Side effects.
Gender and race differences in lipodystrophy symptoms
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Visceral adipose tissue returns to baseline after stopping therapeutic intervention with rHGH
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Raltegravir body composition study: 48-week DEXA results
31 December 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Lipid and metabolic changes with ARV combinations
5 October 2009. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tenofovir and renal safety
5 October 2009. Related: Conference reports, Side effects.
Assessing the cardiovascular impact of HIV, abacavir, and new signals for lopinavir/r
3 June 2009. Related: Conference reports, Side effects.
Intensive smoking cessation programme reports limited success at 6 months
3 June 2009. Related: Conference reports, Side effects.
HDL particle concentration predicts cardiovascular disease in SMART
3 June 2009. Related: Conference reports, Side effects.
CD4 count >250 not predictive of rash-associated hepatoxicity among women initiating nevirapine-based ART in Zambia, Thailand, and Kenya
3 June 2009. Related: Conference reports, Side effects.
Genetic markers linked to early discontinuation of three antiretrovirals
3 June 2009. Related: Conference reports, Side effects.
High rate of rash in HIV negative volunteers combining raltegravir and darunavir
26 December 2008. Related: Conference reports, Side effects.
Bone loss in SMART study
26 December 2008. Related: Conference reports, Side effects.
Parathyroid hormone and vitamin D levels in patients using tenofovir
26 December 2008. Related: Conference reports, Side effects.
Haemoglobin A1c (HbA1c) may underestimate glycaemia in patients with diabetes on HIV therapy
26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Statin use in HIV-positive patients
26 December 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Abacavir and heart disease: SMART study supports an abacavir-associated increased risk of cardiovascular disease
30 October 2008. Related: Conference reports, Antiretrovirals, Side effects.
EMEA state that animal studies support no increased risk of malignancy from contamination of nelfinavir (Viracept) with ethyl mesilate (EMS)
30 October 2008. Related: Antiretrovirals, Side effects.
Ritonavir label updated in the US relating to cardiac arrhythmia reported in high-dose studies
30 October 2008. Related: Antiretrovirals, Side effects.
Bone problems raised in several UK studies
30 August 2008. Related: Conference reports, Side effects.
New-fill used to treat lipoatropy in feet
12 June 2008. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tesamorelin (TH9507) reduces abdominal fat in patients with HIV-related lipodystrophy: 52 week results
2 December 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Case report of efavirenz-associated nephrolithiasis
1 December 2007. Related: Side effects.
Yellow card reporting scheme for doctors and patients in the UK
1 December 2007. Related: Side effects.
30 cases of atazanavir-related kidney stones reported
3 July 2007. Related: Side effects.
Tenofovir and indinavir associated with increased risk of chronic renal failure in EuroSIDA study
3 July 2007. Related: Side effects.
Growth hormone release factor (TH9507) reduces central fat adiposity
4 April 2007. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Further insight into risk and management of cardiovascular disease (CVD) from D:A:D cohort: no additional benefit of metabolic syndrome diagnosis; new HIV-specific CVD risk equations; increasing uptake of lipid lowering drugs but low smoking cessation
4 April 2007. Related: Conference reports, Side effects.
d4T associated with significantly increased risk of type-2 diabetes mellitus
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switching from PIs to NNRTIs has similar effect on TC/HDL ratio as use of lipid lowering drugs in the management of dyslipidaemia
6 December 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
The role of the metabolic syndrome in HIV
15 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Effect of lifestyle modification on risk factors for cardiovascular disease and metabolic syndrome
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pioglitazone reduces peripheral lipoatrophy and improves adipokines without reducing visceral fat
9 October 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Tenofovir did not increase the incidence nephrotoxicity in limited numbers of HIV-positive patients using chemotherapy or HCV-coinfeced patients using ribavirin
9 September 2006. Related: Conference reports, Side effects, Cancer and HIV.
Use of HLA-B*5701 genetic testing to reduce abacavir hypersensitivity reactions
12 May 2006. Related: Conference reports, Side effects.
Regimen durability and toxicity in 36-month follow up on ART in Khayelitsha, South Africa
12 May 2006. Related: Conference reports, Side effects.
D:A:D study shows that PIs rather than NNRTIs drive the previously reported cardiovascular risk of combination antiretroviral therapy
25 March 2006. Related: Conference reports, Side effects.
Interventions for the management of lipodystrophy and metabolic complications
25 March 2006. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Analysis of hepatic events in 2NN study by CD4 entry criteria, levels differences between nevirapine and efavirenz; excess hepatic events in once-daily nevirapine arm linked to single site in Thailand
11 February 2006. Related: Conference reports, Side effects.
Factors associated with sexual dysfunction in HIV patients
11 February 2006. Related: Conference reports, Side effects.
African-Americans in ACTG 5095 had shorter time to virologic failure and grade 3/4 side effects
10 February 2006. Related: Conference reports, Side effects.
Predictors of insulin resistance in first year of therapy
10 February 2006. Related: Conference reports, Side effects.
Monitoring side effects in resource limited countries
13 December 2005. Related: Conference reports, Side effects.
Uridine supplement reverses thymidine-induced lipoatrophy
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Pravastatin increases limb fat in HIV-positive patients with hypercholesterolaemia
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Evidence that facial fat can return after switching from either d4T or AZT, to abacavir or tenofovir
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Niacin has beneficial effect on lipids but no reduction in abdominal fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Gluteal implants used to replace lost buttock fat
13 December 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Fatigue among HIV-positive patients in the era of highly active antiretroviral therapy
13 October 2005. Related: Side effects.
EMEA statement on metabolic and cardiovascular complications of antiretroviral therapy in HIV-infected patients
13 September 2005. Related: Side effects.
EMEA statement on use of antiretroviral treatment in HIV-patients with hepatic impairment and/or HBV/HCV co-infection
13 September 2005. Related: Side effects, Hepatitis coinfection.
Levels of efavirenz 10-fold above minimum target level despite coadministration with rifampicin
15 June 2005. Related: Conference reports, PK and drug interactions, Side effects.
Absolute risk is modest, but cumulative cardiovascular risk of HAART over five years is similar to ‘ever smoked’: new data on gender and age
18 April 2005. Related: Conference reports, Side effects.
Omega-3 supplement effective to reduce triglycerides
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Switch to tenofovir from AZT or d4T improves fat loss and improves lipid parameters compared to abacavir
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Continued use of a thymidine analogue may limit benefit from rosiglitazone when used to treat lipoatrophy
18 April 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
EuroSIDA shows HIV-HCV coinfected patients more likely to stop HAART because of side effects
29 March 2005. Related: Conference reports, Side effects.
Nucleoside analogue-related mitochondrial toxicity and link to lipoatrophy: effect of non-thymidine analogues abacavir and tenofovir
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Potential for uridine to treat mitochondrial toxicity: still only in vitro data
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
rHGH reduces central fat accumulation in adolescent lipodystrophy
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Endothelial dysfunction similar in ARV-experienced and -naive patients
31 January 2005. Related: Conference reports, Side effects.
Pravastatin improves lipid profiles but not endothelial function
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.
Treatment interruptions improve lipids within four weeks: IL-2 has no metabolic effect
31 January 2005. Related: Conference reports, Side effects, Lipodystrophy and metabolic complications.